ArQule Gets a New CEO

4/15/08

Woburn, MA-based ArQule, which is developing several compounds known as kinase inhibitors as potential cancer therapies, said today that Paolo Pucci, a Bayer senior vice president overseeing Bayer-Schering’s global oncology and  therapeutics business, will take over as the company’s new CEO. Pucci succeeds Stephen Hill, a nine-year veteran of the company who announced his approaching departure in January and left ArQule to become president and CEO of Brussels, Belgium-based Solvay Pharmaceuticals on April 1.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can e-mail him at wroush@xconomy.com. Follow @

Next Post

Related Topics

Related Posts

    

Xconomy Events Across the Network

XSITE 2012: The Xconomy Summit on Innovation, Technology & Entrepreneurship

Boston · 6/14/12
8:30 am - 5:00 pm

More Xconomy Events

Xconomy’s Most Popular

  1. Biotech IPOs Start to Show Some Modest Signs of Life
  2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story
  5. Announcing Xconomy’s Napa Summit: Keeping America Growing

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.